Participating Companies

Affimed N.V. [AFMD] US$209 MM MCap
Mo­d­u­lar ROCK™plat­form en­abling mul­ti-spe­cif­ic NK / T-cell bi-and tri-spe­cif­ic Abs. Aug 2018 deal w Ge­nen­tech ($96M up­front / $5B po­ten­tial). – AFM13 in P1b (com­bo) in HL and P2a(mono) in CD30+lym­pho­ma [more in­for­ma­tion]
Amarin Corporation [AMRN] US$6,414 MM MCap
Vas­ce­pa: 1st and on­ly pure EPA ome­ga-3 fat­ty acid ap­proved to low­er trig­lyc­eride lev­els in adults. Pre­sent­ed (+) da­ta from RE­DUCE-IT CV Out­comes trial at AHA [more in­for­ma­tion]
Biohaven Pharmaceuticals, Inc [BHVN] US$1,810 MM MCap
Lead de­vel­op­ment pro­grams in­clude mul­ti­ple com­pounds across its CGRP re­cep­tor an­ta­g­on­ist and glu­ta­mate mo­d­u­la­tion plat­forms. In­ter­nal de­vel­op­ment and re­search with in­tel­lec­tu­al prop­er­ty li­censed from com­pa­nies and in­sti­tu­tions in­clud­ing BMS, As­traZene­ca, Yale Uni­ver­si­ty, Ca­ta­l­ent, ALS Bio­phar­ma and Mas­sachusetts Gen­er­al Hos­pi­tal. [more in­for­ma­tion]
BioTime, Inc [BTX] US$166 MM MCap
Lead (Ph 2) cell re­place­ment can­di­date: OpRe­gen®, reti­nal pig­ment epithe­li­um tran­s­plant ther­a­py: Dry AMD. Lead cell de­liv­ery clin­i­cal pro­gram: Rene­via®: med de­vice de­vel­oped as al­ter­na­tive to adi­pose tis­sue trans­fer pro­ce­dures. Equi­ty in As­te­rias Bio­ther­a­peu­tics (NYSE: AST), On­co­Cyte Cor­po­ra­tion (NYSE: OCX), and AgeX Ther­a­peu­tics (pri­vate) [more in­for­ma­tion]
CASI Pharmaceuticals Inc. [CASI] US$306 MM MCap
Re­ceived MN­PA (f.k.a. CF­DA) ap­pro­val for EVOMELA® (mel­pha­lan for in­jec­tion: mul­ti­ple myelo­ma) on Dec 3, 2018; CF­DA re­view in progress for ZE­VALIN® and MAR­QI­BO® (in-li­censed from Spec­trum Phar­ma). Ac­qd 25 US FDA-ap­proved AN­DAS from San­doz in Jan 2018. [more in­for­ma­tion]
Cellular Biomedicine Group, Inc. [CBMG] US$288 MM MCap
This vali­dates CB­MG's in-house cell man­u­fac­tur­ing ca­pa­bil­i­ties de­vel­oped in part­n­er­ship with Gen­er­al Elec­tric and Ther­mo Fish­er. CB­MG's pro­pri­e­tary im­muno-on­col­o­gy pipe­line in­cludes BC­MA, CD22, TCR-T for HCC and TIL for the treat­ment of NS­CLC and other solid tu­mors. [more in­for­ma­tion]
Iovance Biotherapeutics [IOVA] US$2,764 MM MCap
AS­CO: new in­ter­im da­ta from TIL ther­a­py LN-145 in ad­vanced cer­vi­cal can­cer (ORR 44%, 1 CR, 9 PRs, 2 uPRs) & TIL ther­a­py in ad­vanced me­lano­ma (ORR 38%, 2 CRs, 18 PRs, 1 uPR). [more in­for­ma­tion]
Kadmon Holdings, Inc. [KDMN] US$233 MM MCap
Plat­form of ROCK in­hibi­tors. ROCK2 in­hibi­tor in reg­is­tra­tion trial cGVHD; en­roll­ment com­ple­tion exp 2H19; ini­tial anal­y­sis exp YE. Ph 2 ini­ti­a­tion in scle­ro­der­ma exp in 2019. [more in­for­ma­tion]
NexImmune, Inc.
Anti­gen-spe­cif­ic T cell ther­a­py. Syn­thet­ic nano­par­ti­cles de­c­o­rat­ed w a com­bo of mul­ti­ple tu­mor rel­e­vant anti­gens and co-sti­m­u­la­to­ry sig­nals en­gag­ing di­rect­ly w tar­get­ed T cells. Mul­ti­ple IND fil­ings exp H1'19. [more in­for­ma­tion]
Ph 3 study in pro­ce­du­ral se­da­tion in US. Safe­ty da­ta in ASA III/IV pa­tients in Ph 3 colonos­copy study and Ph 3 bron­chos­copy study. US fil­ing exp by part­n­er Cos­mo Phar­ma­ceu­ti­cals in 4Q18/1Q19. Ini­ti­at­ed Ph 3 in gen­er­al anes­th­e­sia in EU in Ju­ly 2018, exp com­ple­tion 2019. Fa­vor­able safe­ty pro­file of mi­da­zo­lam and at­trac­tive half-life of propo­fol: best of both in­dus­try stan­dards. [more in­for­ma­tion]
Phar­varis is a pre­clin­i­cal stage com­pany fo­cused on bring­ing an oral bradykinin B2 re­cep­tor an­ta­g­on­ist to pa­tients for use as an al­ter­na­tive to in­ject­ed ther­a­pies for hered­i­tary an­gioede­ma (HAE) and other B2 re­cep­tor-me­di­at­ed in­di­ca­tions. [more in­for­ma­tion]
Pieris Pharmaceuticals, Inc. [PIRS] US$211 MM MCap
An­ti­calins (en­gi­neered lipo­calin pro­teins) for re­sp & on­co dis­eas­es. Im­mi­nent da­ta for AZN-part­nered PRS-060 in­haled IL4 for mod-to-se­vere asth­ma. Cash of $128MM in the bank as of March 2019. [more in­for­ma­tion]
Quentis Therapeutics
Lead pro­gram is a first-in-class IRE1&al­pha; in­hibi­tor de­signed to boost an­ti-tu­mor im­mu­ni­ty in can­cer. Quen­tis is pur­su­ing ther­a­pies to ad­dress mul­ti­ple ER stress path­way tar­gets in the tu­mor mi­cro-en­vi­ron­ment, as well as in other dis­eas­es where ER stress plays an im­por­tant role. Quen­tis launched in Fe­bruary 2018 with a $48 mil­lion Se­ries A fi­nanc­ing. [more in­for­ma­tion]
Savara Inc. [SVRA] US$102 MM MCap
Or­phan lung dis­ease; Mol­gradex, Ph 3, in­haled GM-CSF: au­toim­mune pul­mo­nary alve­o­lar pro­tei­no­sis (aPAP), Ph 2a: non­tu­ber­cu­lous my­cobac­te­ria (NTM) lung in­fec­tion [more in­for­ma­tion]
Strongbridge Biopharma [SBBP] US$185 MM MCap
Rare dis­eas­es; Keveyis for PPP 2019 rev­enue gui­dance of $18-20M; Re­cor­lev 2nd Phase 3 top-line re­sults 1Q 2020; NDA sub­mis­sion exp 3Q 2020 [more in­for­ma­tion]
Targovax [TRVX:OS] NKr342 MM MCap
En­gi­neered on­co­lyt­ic virus armed w im­mune-sti­m­u­lat­ing trans­genes for pts w solid tu­mors. Ph 1 and Ph 1/2 trials on­go­ing with mul­ti­ple da­ta read­outs in 2019-2020. CMO de­vel­oped Yer­voy at BMS. [more in­for­ma­tion]
Tessa Therapeutics
On­go­ing Ph III – (na­sopha­ryn­geal can­cer), Ph I – (cer­vi­cal, mov­ing in­to Ph II); mul­ti­ple other as­sets en­ter­ing clin­ic. Key col­labs: Bay­lor, Park­er Inst, St. Jude Chil­dren’s [more in­for­ma­tion]